GlaxoSmithKline and Theravance filed an application with the European Medicines Agency seeking approval to market Anoro, their once-daily inhaler UMEC/VI, as a maintenance treatment for symptom relief in adult patients with chronic obstructive pulmonary disease. The drug is a combination of vilanterol, a long-acting beta agonist, and umeclidinium bromide, a long-acting muscarinic antagonist.

Full Story:
PharmaTimes (U.K.)

Related Summaries